(via TheNewswire)
As McGregor Prepares to Headline UFC 329 on July 11, 2026, the Company Is
Expected to be Exclusively Positioned as MMA.INC’s Sole Peptide Partner
Across Its Global Combat Sports Ecosystem
Highlights
he Company holds an exclusive strategic marketing agreement with MMA.INC, providing direct commercial access to MMA.INC’s global combat sports ecosystem of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 22 countries
VANCOUVER, BRITISH COLUMBIA – TheNewswire - July 8, 2026 – The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") , a publicly traded wellness company building a next generation platform for high quality peptide formulations, today provides an update on its previously announced Exclusive Strategic Marketing Agreement (the “Agreement”) with Mixed Martial Arts Group Limited (“MMA”) (NYSE American: MMA), as global attention on combat sports intensifies ahead of Conor McGregor’s scheduled return to the UFC on July 11, 2026.
McGregor Returns: A Global Moment for Combat Sports
Conor McGregor; former UFC champion and one of the most globally recognized figures in combat sports, is scheduled to headline UFC 329 against Max Holloway on July 11, 2026, at T-Mobile Arena in Las Vegas. The welterweight fight marks McGregor’s first UFC appearance in five years and is widely regarded as one of the most anticipated events on the 2026 combat sports calendar.
McGregor serves as a strategic advisor to MMA.INC, and his return to the octagon is expected to drive significant global viewership, consumer engagement and commercial activity across the combat sports ecosystem. As MMA.INC’s sole and exclusive peptide partner, the Company is expected to be commercially positioned within that ecosystem at a time when audience attention on athletic performance, recovery and wellness is at its highest.
The Company’s Position Inside the Ecosystem
Since entering into the Agreement in May 2026 (see news releases dated May 12, 2026 and May 21, 2026 ), the Company has held the exclusive right to market its peptide products across MMA.INC’s entire digital footprint. No other peptide company has access to the platform. The Company is the only peptide brand integrated into an ecosystem that sits at the intersection of combat sports participation, athletic recovery and performance optimization; categories that attract consumers with high engagement, strong brand loyalty and consistent repeat purchasing behaviour.
The physical demands of Brazilian Jiu-Jitsu, mixed martial arts, wrestling, boxing and related disciplines drive consumer interest in recovery and resilience solutions. The Company believes this creates a natural alignment between its product offering and the audience MMA.INC has assembled.
The Scale of MMA.INC’s Platform
MMA.INC has built what the Company considers the largest digitally connected combat sports ecosystem in the world. As publicly disclosed by MMA.INC1 , the platform now spans over 5 million social media followers, approximately 530,000 user profiles, more than 100,000 active students, over 18,000 published gym profiles and more than 800 verified gym partners across 22 countries. Users access the ecosystem through TrainAlta, BJJLink, Hype and MixedMartialArts.com, all unified under a single sign-on infrastructure.
MMA.INC’s Leadership and Advisory Roster
As publicly disclosed by MMA.INC, members include:
● John Kavanagh; cofounder of MMA.INC and Conor McGregor’s longtime head coach
● Conor McGregor; former UFC champion and strategic advisor to MMA.INC2
● D onald Trump Jr.; strategic advisor to MMA.INC and Director of Trump Media and Technology Group (Nasdaq, NYSE Texas: DJT)
● Laura Sanko; board director of MMA.INC and the first female colour commentator in UFC history
U.S. Manufacturing and Quality Standards
The Company manufactures all of its peptide products in the United States and subjects them to third party testing protocols focused on purity, consistency and quality assurance. The Company views this infrastructure as a competitive advantage as the broader industry moves away from fragmented offshore supply chains and towards domestically-manufactured, quality-controlled alternatives.
How the Economics Work
The Agreement provides for a net revenue share on all sales sourced through MMA.INC’s platform. During the first twelve months, net revenue is split equally between the parties on a 50/50 basis. From month thirteen onward, the split shifts to 75/25 in favour of the Company. A twelve-month tail period applies following any termination, during which the Company continues to pay MMA’s share on referred customers. The Company made no upfront capital investment to secure the partnership.
All peptide products sold under the Agreement are manufactured in the United States and comply with applicable U.S. regulatory requirements, including those set by the U.S. Food and Drug Administration.
Pratap Sandhu, CEO of The Precision Peptide Company, commented:
“Conor McGregor’s return to the UFC is a defining global moment for combat sports, and it puts a spotlight on the entire ecosystem we are now commercially connected to through our exclusive partnership with MMA.INC. With McGregor, Donald Trump Jr., John Kavanagh and Laura Sanko behind MMA.INC, and the Company as the platform’s sole peptide partner, we believe we are positioned in front of one of the largest and most engaged performance driven audiences in the world at this time.
“Combined with our commitment to U.S. manufacturing and third party testing, this partnership positions the Company to become the peptide brand of choice for one of the world’s most performance driven consumer audiences.”
Nick Langton, Founder and CEO of MMA.INC., also commented:
“ We are pleased to have The Precision Peptide Company as our exclusive peptide partner as MMA.INC continues to scale its global ecosystem. The partnership opens a new commercial vertical for MMA.INC in an area where we see strong alignment with our community; recovery, performance, longevity and preventative health.”
Further details regarding product launches, marketing campaigns and commercialization milestones are expected to be announced in subsequent updates.
Sources
1 MMA.INC (NYSE American: MMA) Corporate Presentation, September 2025. Available at [ https://ir.mma.inc/news-events/presentations ].
2 UFC.com, “Conor McGregor Rematches Max Holloway in Welterweight Main Event at UFC 329 Live on Paramount+,” May 2026. [ https://www.ufc.com/news/conor-mcgregor-rematches-max-holloway-welterweight-main-event-ufc-329-live-paramount ].
About The Precision Peptide Company
The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.
For more information, visit:www.precisionpeptidecompany.com
About Mixed Martial Arts Group Limited
With over 5 million social media followers, 530,000 user profiles, 75,000+ active students, 18,000 published gyms and 800 verified gyms across 22 countries across its various assets, MMA.INC continues to transform the martial arts landscape and deliver unparalleled value to its stakeholders:
Get Paid to Train: Engaging in training, streaming, coaching or simply supporting any activity, will earn Experience Points (XP), which is transparently logged on chain and can be redeemed for real rewards.
One Unified Ecosystem: With existing platform assets including BJJLink, TrainAlta, Hype and MixedMartialArts.com, MMA.INC provides a complete platform that covers training, community, content and fandom like no other.
For more information, visitwww.mma.inc
Company Contact
Pratap Sandhu CEO, Corporate Secretary and Director
pratap@precisionpeptidecompany.com
+1 (604) 765-8069
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements relating to: the anticipated commercial benefits and significance of the Company’s exclusive strategic marketing agreement with MMA.INC; the expected ability of the Company to generate revenue through MMA.INC's global combat sports ecosystem; the anticipated impact of the headline fight on consumer engagement, viewership and commercial activity across the MMA.INC ecosystem; the anticipated revenue share arrangement between the Company and MMA.INC, including the transition from a 50/50 to a 75/25 split in favour of the Company; the Company’s positioning as MMA.INC's sole and exclusive peptide partner and the competitive advantage the Company expects to derive therefrom .
Forward-looking information is based on certain key expectations and assumptions made by the Company, including that: the Agreement with MMA.INC will continue in force and the exclusive rights thereunder will not be adversely affected ; the headline fight as currently scheduled and that the event will generate significant global viewership and consumer engagement ; the commercial and marketing activities contemplated under the Agreement will be implemented as currently planned; MMA.INC 's digital ecosystem , including its social media reach , user base and gym network, will continue to operate at or near current scale; no adverse regulatory, scientific, manufacturing, or supply chain developments will materially delay or prevent the Company 's commercialization of its peptide products ; and general business and economic conditions will not change in a manner materially adverse to the Company.
Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, but not limited to: the risk that the Agreement with MMA.INC is terminated, amended or otherwise does not perform as expected; the risk that the headline fight does not proceed as anticipated or does not generate the expected level of viewership or consumer engagement ; the risk that the Company’s exclusive position as MMA.INC's sole peptide partner does not translate into anticipated commercial results; and the risk that adverse regulatory developments affecting peptide products in the United States materially impact the Company’s ability to commercialize its products through the Agreement .
Copyright (c) 2026 TheNewswire - All rights reserved.
© 2026 Canjex Publishing Ltd. All rights reserved.